Ali Eftekharian1, Maryam Amizadeh1. 1. Department of Otorhinolaryngology, Shahid-Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVES/HYPOTHESIS: To evaluate in patients with idiopathic sensorineural hearing loss whether pulse therapy with methylprednisolone leads to better recovery of hearing than traditional oral prednisolone therapy. STUDY DESIGN: Randomized controlled trial. METHODS:Sixty-seven patients diagnosed with idiopathic sensorineural hearing loss were randomly divided into two groups based on therapy. The study group received 500-mg daily intravenous methylprednisolone for 3 consecutive days, followed by 1 mg/kg (maximum 60 mg) oral prednisolone for 11 days (total treatment: 14 days). The control group received 1 mg/kg (maximum 60 mg) oral prednisolone for 14 days. Hearing change was evaluated by comparing initial hearing tests and the third-month hearing tests in three ways: 1) pure tone improvement in each individual tone (0.5, 1, 2, 3, and 4 kHz); 2) word-recognition score improvement; and 3) complete, partial, and no recovery of hearing calculated (as defined by American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guidelines). RESULTS:Sixty of 67 patients, 29 of 34 patients in the study group and 31 of 33 patients in the control group, completed the study. Frequency-specific hearing improvement did not differ significantly among the groups. Word-recognition score improvement was 20.34% ± 27.35% for the study group and 13.41% ± 23.48% for the control group, which had no statistically significant difference. There was also no significant difference in hearing recovery rates for the two groups. CONCLUSION: Pulse therapy with methylprednisolone and traditional oral prednisolone therapy resulted in similar hearing improvement.
RCT Entities:
OBJECTIVES/HYPOTHESIS: To evaluate in patients with idiopathic sensorineural hearing loss whether pulse therapy with methylprednisolone leads to better recovery of hearing than traditional oral prednisolone therapy. STUDY DESIGN: Randomized controlled trial. METHODS: Sixty-seven patients diagnosed with idiopathic sensorineural hearing loss were randomly divided into two groups based on therapy. The study group received 500-mg daily intravenous methylprednisolone for 3 consecutive days, followed by 1 mg/kg (maximum 60 mg) oral prednisolone for 11 days (total treatment: 14 days). The control group received 1 mg/kg (maximum 60 mg) oral prednisolone for 14 days. Hearing change was evaluated by comparing initial hearing tests and the third-month hearing tests in three ways: 1) pure tone improvement in each individual tone (0.5, 1, 2, 3, and 4 kHz); 2) word-recognition score improvement; and 3) complete, partial, and no recovery of hearing calculated (as defined by American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guidelines). RESULTS: Sixty of 67 patients, 29 of 34 patients in the study group and 31 of 33 patients in the control group, completed the study. Frequency-specific hearing improvement did not differ significantly among the groups. Word-recognition score improvement was 20.34% ± 27.35% for the study group and 13.41% ± 23.48% for the control group, which had no statistically significant difference. There was also no significant difference in hearing recovery rates for the two groups. CONCLUSION: Pulse therapy with methylprednisolone and traditional oral prednisolone therapy resulted in similar hearing improvement.
Authors: Stefan K Plontke; Christoph Meisner; Sumit Agrawal; Per Cayé-Thomasen; Kevin Galbraith; Anthony A Mikulec; Lorne Parnes; Yaamini Premakumar; Julia Reiber; Anne Gm Schilder; Arne Liebau Journal: Cochrane Database Syst Rev Date: 2022-07-22
Authors: Shuihua Wang; Ming Yang; Sidan Du; Jiquan Yang; Bin Liu; Juan M Gorriz; Javier Ramírez; Ti-Fei Yuan; Yudong Zhang Journal: Front Comput Neurosci Date: 2016-10-19 Impact factor: 2.380
Authors: Nadera Ahmadzai; Shaun Kilty; Wei Cheng; Leila Esmaeilisaraji; Dianna Wolfe; James P Bonaparte; David Schramm; Elizabeth Fitzpatrick; Vincent Lin; Becky Skidmore; David Moher; Brian Hutton Journal: PLoS One Date: 2019-09-09 Impact factor: 3.240